Published in Gene Therapy Weekly, January 2nd, 2003
"Morpholino antisense oligonucleotides act by blocking translation of their target gene products and are effective tools for downregulating gene expression," said L.S. Siddall and colleagues, University of Western Ontario, who conducted a study "to define treatment conditions for the use of morpholino oligonucleotides (MOs) in mammalian preimplantation embryos, and to employ MOs to target genes and study gene function in the early embryo."
The researchers said, "For the first time, ethoxylated...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.